Pharmacogenomics and personalized medicine in neuropsychiatry.
Despite the need for more effective treatments for psychiatric disorders, development of new medications has stalled. Here we discuss the promise of personalized medicine in developing more efficacious and individualized pharmacotherapies that take into account genetic variation and target groups of patients who share biology, not just symptoms.
National Institutes of Health, US Department of Health and Human Services, Bethesda, MD 20892-3719, USA. mcmahonf@mail.nih.gov
Francis J
FJ
McMahon
Thomas R
TR
Insel
D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D014644:Genetic Variation; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics*; D058027:Neuropsychiatry; D010597:Pharmacogenetics / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*
D003577:Cytochrome P-450 Enzyme System